OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BACTIQ$3.3056

Bactiquant A/S

Advanced Medical Equipment & TechnologyVerified

Bactiquant A/S has a high price-to-book ratio of 7.17, indicating that the market values the company significantly above its book value. The company's liquidity position is strong, with a current ratio of 6.02, suggesting it has ample short-term assets to cover its liabilities. However, the company's operating cash flow is negative at -10,508,000 DKK, and its free cash flow is also negative at -12,257,120 DKK, indicating that it is not generating positive cash from operations. The company's profitability is weak, with a return on equity of -0.8014 and a return on assets of -0.4928, both significantly below the industry median. The gross profit is negative at -2,192,640 DKK, and the operating income is also negative at -12,497,520 DKK, indicating that the company is not yet profitable. Bactiquant A/S operates through seven business segments, including Aquaculture, Water Utility, Industry, Data Centres, Oil and Gas, Legionella Risk Assessment, and Research Institutions. The company serves customers across five continents, with a focus on public water utility companies and industries requiring water cooling or wastewater treatment. However, the revenue concentration data is not available, so it is unclear if the company is overly reliant on any particular segment or geographic region. The company's growth trajectory is uncertain, as the outlook for the current fiscal year and the next fiscal year is not provided. The company's revenue has not been provided for previous years, so it is difficult to assess its historical growth. However, the company's market cap of 123,822,124.8 DKK suggests that the market has some optimism about its future potential. The risk assessment indicates that the company has low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio is 0.5, indicating a moderate level of leverage. The company's capital structure is relatively strong, with total equity of 17,260,620 DKK and total liabilities of 10,807,680 DKK. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent financial performance is characterized by negative operating and net income, but its strong cash and equivalents position of 17,867,810 DKK provides a buffer against short-term liquidity risks.

30-day price · BACTIQ(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyBactiquant A/S
TickerBACTIQ.CO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Bactiquant A/S develops technology to monitor bacterial contamination levels in water, serving industries such as public water utilities, aquaculture, and industrial water treatment.

Classification. Bactiquant A/S is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Bactiquant A/S has a high price-to-book ratio of 7.17, indicating that the market values the company significantly above its book value. The company's liquidity position is strong, with a current ratio of 6.02, suggesting it has ample short-term assets to cover its liabilities. However, the company's operating cash flow is negative at -10,508,000 DKK, and its free cash flow is also negative at -12,257,120 DKK, indicating that it is not generating positive cash from operations. The company's profitability is weak, with a return on equity of -0.8014 and a return on assets of -0.4928, both significantly below the industry median. The gross profit is negative at -2,192,640 DKK, and the operating income is also negative at -12,497,520 DKK, indicating that the company is not yet profitable. Bactiquant A/S operates through seven business segments, including Aquaculture, Water Utility, Industry, Data Centres, Oil and Gas, Legionella Risk Assessment, and Research Institutions. The company serves customers across five continents, with a focus on public water utility companies and industries requiring water cooling or wastewater treatment. However, the revenue concentration data is not available, so it is unclear if the company is overly reliant on any particular segment or geographic region. The company's growth trajectory is uncertain, as the outlook for the current fiscal year and the next fiscal year is not provided. The company's revenue has not been provided for previous years, so it is difficult to assess its historical growth. However, the company's market cap of 123,822,124.8 DKK suggests that the market has some optimism about its future potential. The risk assessment indicates that the company has low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio is 0.5, indicating a moderate level of leverage. The company's capital structure is relatively strong, with total equity of 17,260,620 DKK and total liabilities of 10,807,680 DKK. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent financial performance is characterized by negative operating and net income, but its strong cash and equivalents position of 17,867,810 DKK provides a buffer against short-term liquidity risks.
Key takeaways
  • Bactiquant A/S has a high price-to-book ratio of 7.17, indicating that the market values the company significantly above its book value.
  • The company's profitability is weak, with a return on equity of -0.8014 and a return on assets of -0.4928.
  • Bactiquant A/S operates through seven business segments, including Aquaculture, Water Utility, and Industry, serving customers across five continents.
  • The company's growth trajectory is uncertain, as the outlook for the current and next fiscal years is not provided.
  • The risk assessment indicates that the company has low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyDKK
Revenue$8.3M
Gross profit-$2.2M
Operating income-$12.5M
Net income-$13.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$10.5M
CapEx$0.00
Free cash flow-$12.3M
Total assets$28.1M
Total liabilities$10.8M
Total equity$17.3M
Cash & equivalents$17.9M
Long-term debt$8.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$3.30
Market cap$123.8M
Enterprise value$114.6M
P/E
Reported non-GAAP P/E
EV/Revenue13.8
EV/Op income
EV/OCF
P/B7.2
P/Tangible book7.2
Tangible book$17.3M
Net cash$9.2M
Current ratio6.0
Debt/Equity0.5
ROA-49.3%
ROE-80.1%
Cash conversion76.0%
CapEx/Revenue0.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 3 companies
MetricBACTIQActivity
Op margin-150.2%19.4% medp25 17.8% · p75 22.0%bottom quartile
Net margin-166.3%17.7% medp25 16.4% · p75 19.0%bottom quartile
Gross margin-26.4%73.5% medp25 71.3% · p75 75.8%bottom quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue0.0%4.3% medp25 3.9% · p75 4.3%bottom quartile
Debt / equity50.0%41.5% medp25 29.2% · p75 51.3%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 07:43 UTC#28394197
Market quoteclose DKK 3.30 · shares 0.04B diluted
no public URL
2026-05-04 07:43 UTC#dff6316a
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 07:44 UTCJob: 3e84f95b